Αρχική World News Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with... World News Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC Από Ogkologos - 4 Ιουνίου, 2025 833 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer 2 Αυγούστου, 2021 Reflections 26 Μαΐου, 2021 Fructose Fuels Cancer Growth Indirectly, Lab Study Finds 14 Ιανουαρίου, 2025 Cliff Collapse Kills Woman Celebrating Breast Cancer Victory and 2 of... 5 Αυγούστου, 2019 Φόρτωση περισσοτέρων HOT NEWS FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated... Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App Building Your Fort of Support: Tips from a Breast Cancer Social... Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment...